Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended): A compound selected from: a compound of Formula (I):



(I)

~~and~~ or a salt, solvate or physiologically functional derivative thereof, wherein:

R^1 ~~represents~~ is hydrogen, halogen or C_1-C_3alkyl;

R^2 ~~represents~~ is a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

Z ~~represents a linker unit selected from:~~ is $-(CH_2)_n-$ [[;]] , $-CH=CH-(CH_2)_m-$ [[;]] , $-(CH_2)_pNHC(O)-$ [[;]] , $-(CH_2)_pNHC(O)NH-$ [[;]] , $-(CH_2)_pNHC(O)O-$ [[;]] , $-(CH_2)_pSO_2NR^3-$ [[;]] , $-(CH_2)_pNR^3SO_2-$ [[;]] , $-(CH_2)_pO-$ ~~and~~ or $-O-$;

n ~~represents an integer selected from~~ is 2, 3 ~~and~~ or 4;

m ~~represents an integer selected from~~ is 0, 1 ~~and~~ or 2;

p ~~represents an integer selected from~~ is 1 ~~and~~ or 2; and

R^3 represents hydrogen or C_1-C_4alkyl, with the proviso that when R^1 is H, Z is $-(CH_2)_n-$ and n [[=]] is 2 or 3, R^2 is other than indol-3-yl.

2. (Currently Amended): A compound according to claim 1 wherein R^1 ~~represents~~ is hydrogen, fluorine or methyl.

3. (Currently Amended): A compound according to claim 2 wherein R^1 ~~represents~~ is hydrogen.

4. (Currently Amended): A compound according to claim 1 wherein Z ~~represents~~ is $-(CH_2)_pO-$ or $-(CH_2)_n-$.

5. (Currenlty Amended): A compound according to claim 4 wherein Z ~~represents~~ is $-(CH_2)_n-$ and n ~~represents an integer selected from~~ is 2, 3 or 4.

6. (Original): A compound according to claim 5 wherein Z is $-(CH_2)_n-$ and n is 2.

7. (Currently Amended): A compound according to claim 4 wherein Z ~~represents~~ is $-(CH_2)_pO-$ and n ~~represents~~ is 1.

8. (Currently amended): A compound according to claim 1 ~~any preceding claim~~ wherein R^2 is a 10-member bi-cyclic ring system.

9. (Original): A compound according to claim 8 wherein R^2 is naphthyl.

10. (Currently amended): A compound according to claim 8 wherein R^2 is a 10-member ring system having ~~either~~ 1 or 2 heteroatoms.

11. (Currently Amended): A compound according to claim 10 wherein R^2 ~~includes~~ contains 1 or 2 nitrogen heteroatoms.

12. (Currently amended): A compound according to claim 8 ~~any one of claims 9, 10 or 11~~ wherein R^2 is selected from the group consisting of:



13. (Currently amended): A compound according to claim 8 wherein R^2 is substituted with one or more groups ~~selected from~~ which are C_1-C_2alkyl, -C(O)Me, =O ~~and~~ or C_1-C_3alkoxy.

14. (Currently amended): A compound according to claim 13 wherein R^2 is substituted with one or more groups ~~selected from~~ which are methyl ~~and~~ or methoxy.

15. (Currently amended): A compound according to claim 1 ~~any one of claims 1-7~~ wherein R^2 is a 9-member ring system selected from the group consisting of fused aryl-cycloalkyl, fused aryl and fused heteroaryl systems.

16. (Currently amended): A compound according to claim 15 wherein R^2 ~~includes~~ contains 1 to 3 heteroatoms ~~selected from~~ which are S, O or N.

17. (Currently amended): A compound according to claim 15 ~~or claim 16~~ wherein R^2 is selected from the group consisting of:



wherein R^4 ~~represents~~ is hydrogen, methyl, CO_2H or CO_2Me.

18. (Currently Amended): A compound according to claim 17 wherein R^2 is substituted with one or more groups ~~selected from~~ which are C_1-C_3alkyl -C(O)Me, =O, C_1-C_3alkoxy, CO_2H and CO_2Me.

19. (Currently Amended): A compound according to claim 18 wherein ~~R2~~ R^2 is substituted with methyl or methoxy.

Claims 20-26. (Cancelled).

27. (Currently Amended): A method for the treatment of a human or animal subject having a condition where under-activation of the HM74A receptor contributes to the condition or where activation of the receptor will be beneficial, which method comprises administering to said human or animal subject an effective amount of a compound ~~selected from a compound~~ of Formula (Ia):



(Ia)

~~and~~ or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, wherein:

R^1 ~~represents~~ is hydrogen, halogen or C_1-C_3alkyl;

R^2 ~~represents~~ is a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

Z ~~represents a linker unit selected from:~~ is $-(CH_2)_n-$ [[;]] , $-CH=CH-(CH_2)_m-$ [[;]] , $-(CH_2)_pNHC(O)-$ [[;]] , $-(CH_2)_pNHC(O)NH-$ [[;]] , $-(CH_2)_pNHC(O)O-$ [[;]] , $-(CH_2)_pSO_2NR^3-$ [[;]] , $-(CH_2)_pNR^3SO_2-$; ~~and~~ or –O– ;

n ~~represents an integer selected from~~ is 2, 3 ~~and~~ or 4;

m ~~represents an integer selected from~~ is 0, 1 ~~and~~ or 2;

p ~~represents an integer selected from~~ is 1 ~~and~~ or 2; and

R^3 ~~represents~~ is hydrogen or C_1-C_4alkyl.

28. (Currently Amended): A method for the treatment of a human or animal subject having a disorder of lipid metabolism ~~including dislipidaemia or hyperlipoproteinaemia~~ or having an inflammatory disease ~~or condition~~, which method comprises administering to said human or animal subject an effective amount of a compound ~~selected from a compound~~ of Formula (Ia):



(Ia)

~~and~~ or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, wherein:

R^1 ~~represents~~ is hydrogen, halogen or C_1-C_3alkyl;

R^2 ~~represents~~ is a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

Z ~~represents a linker unit selected from:~~ is $-(CH_2)_n-$ [[;]] , $-CH=CH-(CH_2)_m-$ [[;]] , $-(CH_2)_pNHC(O)-$ [[;]] , $-(CH_2)_pNHC(O)NH-$ [[;]] , $-(CH_2)_pNHC(O)O-$ [[;]] , $-(CH_2)_pSO_2NR^3-$ [[;]] , $-(CH_2)_pNR^3SO_2-$; ~~and~~ or –O– ;

n ~~represents an integer selected from~~ is 2, 3 ~~and~~ or 4;

m ~~represents an integer selected from~~ is 0, 1 ~~and~~ or 2;

p ~~represents an integer selected from~~ is 1 ~~and~~ or 2; and

R^3 ~~represents~~ is hydrogen or C_1-C_4alkyl.

29. (Currently amended): A pharmaceutical formulation comprising a compound according to claim 1 ~~any one of claims 1-19~~ in admixture with one or more physiologically acceptable diluents, excipients or carriers.

30. (Currently amended): A combination for administration together or separately, sequentially or simultaneously in separate or combined pharmaceutical formulations, said combination comprising a compound according to claim 1 ~~any one of claims 1-19~~ together with another therapeutically active agent.

31. (Currently amended): A pharmaceutical formulation comprising a compound according to claim 1 ~~any one of claims 1-19~~, a further active ingredient selected from the group consisting of statins, fibrates, bile-acid binding resins and nicotinic acid and one or more physiologically acceptable diluents, excipients or carriers.

32. (Currently amended): A process for the preparation of a compound according to claim 1 ~~any one of claims 1-19~~, the ~~method~~ process comprising the steps of:

i. alkylation of an aromatic alcohol with methyl 2-[(chloroacetyl)amino]benzoate;

ii hydrolysis of methyl ester using lithium hydroxide; and

iii where desired or necessary converting a resultant free ~~acid or base~~ base or acid compound of [[f]] Formula (I) into a physiologically acceptable salt ~~form~~ or free base ~~vice versa~~ or converting one salt ~~form~~ into another physiologically acceptable salt ~~form~~.

33. (Currently amended): A process for the preparation of a compound according to claim 1 ~~any one of claims 1-19~~, the ~~method~~ process comprising the steps of:

i. formation of an amide between the amine group of anthranilic acid (2-amino-bezoic acid) and an activated acyl transfer reagent derived from a carboxylic acid; and

ii where desired or necessary converting a resultant free ~~acid or base~~ base or acid compound of [[f]] Formula (I) into a physiologically acceptable salt ~~form~~ or free base ~~vice versa~~ or converting one salt ~~form~~ into another physiologically acceptable salt ~~form~~.

34. (New): A method according to claim 28 wherein the disorder of lipid metabolism is dislipidaemia or hyperlipoproteinaemia.